News

Several North American advocacy and research non-profit organizations will host a virtual flash mob June 29, on World Scleroderma Day, to raise awareness for the disease. The social media event will happen on the heals of more than 100 fundraising walks, tributes and other events held during June’s Scleroderma Awareness Month. Organizations heading up…

A small study by researchers in Greece showed that B-cell depletion through “off-label” use of an approved drug may help to treat skin fibrosis in people with systemic sclerosis (SSc), and identified specific molecules of likely importance to this process. The article, “B cell depletion therapy upregulates Dkk-1 skin expression in patients…

Corbus Pharmaceuticals recently announced that its Phase 2 clinical trial assessing the drug Resunab as a potential treatment for diffuse cutaneous systemic sclerosis is now fully enrolled. The study (NCT02465437) is a randomized, double-blind and placebo-control trial, taking place at nine sites across the U.S., to evaluate Resunab’s efficacy, tolerability, safety and pharmacokinetics…

Protagen AG, a biotechnology company specializing in diagnostic tests for autoimmune diseases, announced that their product Multilisa BICD2, for the diagnosis of scleroderma, gained CE marking.

Low levels of female sex hormones called estrogens might drive disease processes leading to skin fibrosis in scleroderma, according to a recent study evaluating the effect of estrogen on fibrosis in mice. The findings indicate that estrogen therapy might be used to harness fibrotic processes in women — an idea…

An easy-to-install heart monitor detects potentially deadly heart arrhythmias in patients with scleroderma without any known heart disease, according to a study presented at the European League Against Rheumatism Annual Congress (EULAR 2016), June 8-11 in London. The study underscores the need to identify patients at risk for heart disease to offer…

The German pharmaceutical company Medac, in August, will begin Phase 3 of a clinical trial to access the therapeutic potential of terguride, a disease-modifying drug for the treatment of diffuse cutaneous systemic sclerosis. Terguride is a serotonin receptor blocker, acting at two particular serotonin receptors called 5-HT2A and 5-HT2B. Medac is convinced…

Japanese scientists have discovered that endothelin-1 (ET-1) signaling through its B-type receptor contributes to the development of skin fibrosis. The finding suggests that ETB can be selectively targeted in new attempts to develop better antifibrotic drugs based on endothelin blockage. Scientists have long suspected that ET-1 signaling contributes to the…

Seeing someone wearing mittens on a warm spring day could make you wonder why — and it could be that person has scleroderma. A middle-age woman with no wrinkles can also be a tell-tale sign of scleroderma. The chances that people don’t know the symptoms or challenges of scleroderma are quite high…

Cytori Therapeutics recently announced that its FDA-approved Phase 3 STAR clinical trial evaluating ECCS-50 has enrolled and treated its 80th patient, reaching 100 percent of its target enrollment. Because of the strong interest and fast screening across the trial clinical sites, additional patients will be enrolled, so the final enrollment will…